Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics, Inc. has released an updated corporate presentation detailing interim responder analysis data from its Phase 3 CAPTIVATE trial for claseprubart in CIDP. The presentation also highlighted positive Phase 2 MaGic trial results for claseprubart in gMG. The company reported approximately $1.2 billion in cash as of March 31, 2026, providing a runway into 2030. An early 'GO' decision was made for the CAPTIVATE trial based on interim responder analysis.

Dianthus Therapeutics granted non-qualified stock options for an aggregate of 60,000 shares of its common stock to three newly-hired, non-executive employees on June 1, 2026. These inducement grants, approved by the Company's independent Compensation Committee, have a 10-year term and an exercise price of $89.45 per share. The options will vest 25% on the first anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent 36 months.

Dianthus Therapeutics, Inc. announced its participation in two investor conferences in June 2026. Ryan Savitz, EVP, CFO and CBO, will attend the 2026 Jefferies Global Healthcare Conference on June 3, 2026. Marino Garcia, CEO, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Both executives are scheduled to host one-on-one investor meetings, and webcasts of their presentations will be accessible on the company's investor relations website.

Dianthus Therapeutics reported a net loss of $40.8 million for the first quarter of 2026, an increase from $29.5 million in the prior year, primarily due to higher research and development and general and administrative expenses. However, the company significantly bolstered its financial position by raising approximately $719.0 million in gross proceeds from a public offering in March 2026. This financing activity led to a substantial increase in cash and cash equivalents to $627.7 million as of March 31, 2026, and is expected to fund operations for at least twelve months.

Dianthus Therapeutics reported its Q1 2026 financial results and highlighted significant business achievements. The company announced an early GO decision in the claseprubart CIDP CAPTIVATE study and received Orphan Drug Designation for claseprubart in Myasthenia Gravis. Dianthus also strengthened its balance sheet by raising approximately $719 million in a public offering, resulting in $1.2 billion in cash, cash equivalents, and investments as of March 31, 2026, providing a runway into 2030. The net loss for Q1 2026 was $40.8 million, or $0.85 per share.

Dianthus Therapeutics, Inc. granted inducement equity awards on May 1, 2026, to six newly-hired, non-executive employees. These grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 135,000 shares of common stock. The options have a 10-year term and an exercise price of $87.42 per share, vesting 25% on the first anniversary and in equal monthly installments for the following 36 months.